犬のミトラル弁の修復中に心臓麻痺溶液を用いた薬理学的除細動の臨床的有用性
K Kurogochi1, Y Nii2, A Chen2
1JASMINE Veterinary Cardiovascular Medical Center, 1-8-37 Nakagawa, Tsuzuki, Yokohama, Kanagawa, 224-0001, Japan; Department of Clinical Sciences, North Carolina State University, College of Veterinary Medicine, Raleigh, NC, 27607, USA.
まとめ
薬理学的除細動は,犬のミトラル弁の修復における再注血性心房細動 (VF) を効果的に解消した. 犬のVFの治療には,平均4. 0mL/ kgの心臓麻痺が単発投与で成功しました.
科学分野:
- 獣医心臓科
- 心血管外科
- 犬の医学
背景:
- 犬のオープンハート外科手術の際に発生する合併症は,再注射性心房細動 (VF) です.
- 標準的な薬理学的除細動技術は,犬の処置では十分に確立されていません.
- 犬におけるミトラル弁の修復は,VFの管理を調査するための適切な臨床シナリオです.
研究 の 目的:
- ミトラル弁の修復を受ける犬における薬理学的除細動の臨床的有用性を評価する.
- 再注血性VFの治療におけるカリウム結晶性心臓麻痺の有効性を決定する.
- この患者集団における再注射性VFの予測要因を特定する.
主な方法:
- ミトラル弁の修復を受けた402匹の飼い犬を遡及的に分析した.
- クロスクランプの解離後に心房細動 (VF) を経験した症例の調査.
- 40mEq/ Lのカリウム結晶性心筋麻痺を,薬理学的除細動のために大動脈根カテーテル経由で投与する.
主要な成果:
- 17. 6% (70/397) の症例でクロスクランプ解離後に心房細動 (VF) が起こりました.
- 薬理学的な除細動は,電気的介入なしに,69件の試行でVFを成功裏に解決しました.
- 一回投与の心臓麻痺 (中位は3. 90mL/ kg) は45例で有効であり,24例では複数の投与が必要であった.
結論:
- 薬理学的除細動は,犬のミトラル弁の修復における再注血VFの管理のための実行可能で効果的な選択肢です.
- 約4. 0mL/ kgの中位値で,心臓麻痺は単一投与で成功しました.
- 低用量の心臓麻痺は,成功した除細動のために複数の投与が必要になる可能性があります.
関連する概念動画
01:30Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
75
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75
01:26Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
01:25Mitral Regurgitation III: Medical Management
30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33